Your Health, We Care
Release date: 2026-07-15 15:25:29 Recommended: 12
Filgotinib has not been studied in individuals under 18 years of age; safety, efficacy, and pharmacokinetic data are lacking. Therefore, it is strictly prohibited for use in children and adolescents. Regarding drug interactions, special attention should be paid to immunosuppressive agents (e.g., cyclosporine, tacrolimus) as they may increase the risk of excessive immunosuppression; concomitant use requires close monitoring. In addition, certain cardiovascular drugs (diltiazem, carvedilol) and the lipid-lowering agent fenofibrate may inhibit CYP3A4 or P-glycoprotein pathways, affecting the metabolic clearance of filgotinib and potentially leading to elevated blood concentrations. Dose adjustment or avoidance of co-administration under medical guidance is recommended. Before taking filgotinib, please inform your doctor of all prescription drugs, over‑the‑counter medicines, herbal products, and dietary supplements you are using. Furthermore, this product contains lactose monohydrate (76 mg in 100‑mg tablets, 152 mg in 200‑mg tablets). For patients with rare hereditary conditions such as lactose intolerance, Lapp lactase deficiency, or glucose‑galactose malabsorption, gastrointestinal discomfort may occur; consult your doctor in advance about its suitability.
Filgotinib is contraindicated during pregnancy, as animal studies suggest that high doses may cause fetal developmental abnormalities, and human pregnancy data are insufficient to rule out teratogenic risk. If you become pregnant while taking this drug, stop the medication immediately and contact your doctor for prenatal counseling and ultrasound monitoring. To avoid unintended pregnancy, women of childbearing potential must use highly effective contraceptive methods (e.g., oral combined contraceptives, intrauterine devices, or barrier methods combined with spermicides) during treatment and for at least 1 week after the last dose. Monthly pregnancy testing is recommended, especially for those with irregular menstrual cycles. Regarding breastfeeding, it is unknown whether filgotinib is excreted into human milk, but many small‑molecule drugs can pass into breast milk and may affect the neonatal immune system. Therefore, after weighing benefits and risks, it is recommended to completely stop breastfeeding during treatment and switch to infant formula. If you plan to breastfeed, you should wait for a sufficient period (at least 5 half‑lives, approximately 1 week or more) after stopping the drug and obtain medical evaluation before resuming. For males with fertility concerns, current data are limited, but generally it is advisable to consult a reproductive specialist before attempting conception.
Common adverse reactions of filgotinib include dizziness and vertigo, especially at the start of treatment or during dose titration. These symptoms may affect your reaction time and balance, thereby impairing the ability to drive motor vehicles, operate precision machinery, or perform work at heights. If you experience light‑headedness, rotational vertigo, or unsteadiness after taking the drug, you should avoid such activities until the symptoms completely resolve. At the same time, do not consume alcohol or use other central nervous system sedatives concomitantly, as they may worsen dizziness. Regarding excipients, this product contains lactose. For most patients this is not a concern, but if you have been diagnosed with hereditary galactose intolerance, total lactase deficiency, or glucose‑galactose malabsorption, you may experience bloating, diarrhea, or abdominal pain due to inability to metabolise lactose. In that case, inform your doctor in advance; they may recommend a lactose‑free alternative. Even if you do not have the above hereditary conditions, if you have previously experienced gastrointestinal symptoms after consuming dairy products, you should also proactively disclose this so that the pharmacist can assess potential tolerance.
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
